Tiago Biachi, MD, PhD, reviews how data from the CORRECT, SUNLIGHT, and FRESCO trials inform later-line treatment selection in refractory mCRC.
Exploring Novel Second- and Third-Line Approaches in Metastatic Colorectal Cancer
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
3
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5